Question 1

What is CABOZANTINIB used for?

Accepted Answer

CABOZANTINIB (brand name COMETRIQ) is a Other indicated for 1 INDICATIONS AND USAGE COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 ).

Question 2

How does CABOZANTINIB work?

Accepted Answer

CABOZANTINIB works through the following mechanism: 12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment..

Question 3

What are the most common side effects of CABOZANTINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for CABOZANTINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is CABOZANTINIB the same as COMETRIQ?

Accepted Answer

COMETRIQ is a brand name for CABOZANTINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

CABOZANTINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations